Seborrheic Dermatitis: Diagnosis and Management Strategies

Definition and Epidemiology

Seborrheic dermatitis is a common, chronic inflammatory condition affecting 1-3% of the general population, with higher prevalence in males (2-3:1 ratio). It typically manifests as erythematous, scaly plaques on sebaceous gland-rich areas: scalp (most common), face (nasolabial folds, cheeks, eyebrows), upper chest, and intertriginous areas. Onset occurs most commonly in the second to fourth decades of life, with a second peak in elderly populations (5-10% of adults >60 years).

Pathophysiology and Etiology

Malassezia Yeast Role: Seborrheic dermatitis is associated with overgrowth of Malassezia species (formerly Pityrosporum), lipophilic yeasts that are part of normal skin flora. Malassezia globosa and M. furfur predominate. These yeasts metabolize sebaceous lipids through lipase activity, producing irritating metabolites (oleic acid, pityrosporum ovale antigens) that trigger abnormal immune responses in genetically predisposed individuals.

Immune Dysregulation: Seborrheic dermatitis represents Th1/Th2 mixed immune response. Malassezia-specific IgG and IgM antibodies are elevated; cellular immunity shows enhanced Th1 (TNF-α, IFN-γ) and Th17 (IL-17) responses. IL-8, IL-1, and TNF-α drive neutrophilic infiltration and inflammation.

Genetic Factors: Family history is present in 25-30% of cases, suggesting genetic predisposition. HLA associations (HLA-B57) have been identified in some populations.

Clinical Features and Presentation

Classic Presentation: Erythematous to yellowish plaques with overlying oily, greasy scale. Scale is often described as "butter-like" or "yellow-waxy." Lesions are usually non-pruritic to mildly pruritic, distinguishing SD from atopic dermatitis (where itch dominates). Mild burning or stinging may occur, particularly with facial involvement.

Scalp Involvement (Pityriasis Capitis): Diffuse scalp scaling with preservation of hair (no hair loss). May range from mild flaking to thick, adherent scale. Often accompanied by oily scalp appearance.

Facial SD: Affects nasolabial folds, eyebrows, glabella, and ears (external ear canal involvement is common). Eyelid margin involvement is frequent; inflammation of meibomian glands contributes to blepharitis and rosacea-like appearance.

Associated Conditions

Seborrheic dermatitis occurs with increased frequency in: (1) HIV infection and AIDS: SD affects 3-18% of HIV+ patients and 80-90% of AIDS patients; severity correlates with CD4+ count. (2) Neurologic disease: Parkinson's disease (40-80% prevalence, 10-fold increase versus general population). (3) Mental health conditions: Depression, psychiatric medications. (4) Stress and seasonal variation: Winter exacerbation common in temperate climates.

Diagnosis and Differential Diagnosis

Diagnosis is clinical based on characteristic distribution (scalp, face, chest) and appearance (oily, greasy scale on erythematous base). Differential diagnoses include: Atopic dermatitis (severe pruritus, different distribution), psoriasis (non-greasy scale, nail involvement, extensor predominance), tinea capitis (hair loss, KOH preparation positive for fungal elements, Malassezia is yeast not dermatophyte), and rosacea (facial telangiectasia, absence of scale).

KOH Preparation: Potassium hydroxide preparation of scale may show yeast forms, but is not required for diagnosis. Culture is rarely performed and lacks clinical utility.

First-Line Treatment: Topical Antifungals

Ketoconazole: Ketoconazole 2% shampoo or cream is highly effective, directly targeting Malassezia growth. Use ketoconazole shampoo twice weekly, lathering for 3-5 minutes before rinsing. Clinical improvement occurs within 2-4 weeks. Ketoconazole cream (2%) applied twice daily is preferred for facial involvement and severe disease. Well-tolerated with minimal systemic absorption when used as directed.

Zinc Pyrithione: Zinc pyrithione 1-2% shampoo (Head & Shoulders, Selsun Blue) is available over-the-counter and provides comparable efficacy to ketoconazole. Use 2-3 times weekly. Onset of action is slower (4-6 weeks); patient compliance may be better due to availability and cost.

Selenium Sulfide: Selenium sulfide 2.5% suspension (Selsun Blue) and 1% products available OTC provide anti-Malassezia activity. Disadvantages include staining of clothes/hair, sulfur odor, and potential for skin irritation. Use 1-2 times weekly. Systemic absorption is minimal with normal use.

Topical Corticosteroids

Topical corticosteroids reduce inflammation and pruritus rapidly but do not address underlying Malassezia overgrowth; monotherapy with TCS alone results in high relapse rates (>80% within 3-6 months). Recommended approach: Combine antifungal therapy with low-to-mid-potency TCS (hydrocortisone 1% or desonide 0.05%) for facial involvement and mild disease; apply TCS twice daily for 1-2 weeks, then taper as inflammation resolves while continuing antifungal.

Mid-potency agents (triamcinolone 0.1% cream) are appropriate for moderate SD with significant inflammation on trunk and extremities; limit duration to 2-3 weeks to avoid skin atrophy.

Topical Calcineurin Inhibitors

Tacrolimus 0.1% ointment and pimecrolimus 1% cream are effective alternatives for facial seborrheic dermatitis, particularly in patients requiring long-term management or concerned about TCS side effects. Clinical improvement requires 3-4 weeks; efficacy is comparable to mid-potency TCS. These agents lack atrophy risk and are valuable for treatment of eyelid and periocular seborrheic dermatitis.

Systemic Antifungals

Systemic antifungals are rarely indicated but may be considered for: (1) severe, extensive seborrheic dermatitis unresponsive to topical therapy, (2) immunocompromised patients (AIDS, post-transplant). Itraconazole (100-200mg daily) and terbinafine (125-250mg daily) achieve clinical improvement but relapse is common after discontinuation. These agents require monitoring for hepatotoxicity and drug interactions and are reserved for severe cases.

Maintenance Therapy and Relapse Prevention

Seborrheic dermatitis is a chronic condition with relapse in 80% of patients within 1-3 months of treatment discontinuation. Long-term maintenance with lower-frequency antifungal use (ketoconazole shampoo once weekly or zinc pyrithione 1-2 times weekly) significantly reduces relapse rates. Some patients benefit from cyclic therapy: active treatment during winter months (increased incidence) with reduced frequency during summer.

Special Populations

Infants and Children: Cradle cap (seborrheic dermatitis of infant scalp) typically self-resolves by age 4-5 years. Treatment includes soft-bristled brush with mineral oil massage, zinc pyrithione shampoo, or ketoconazole if indicated.

HIV/AIDS Patients: SD in advanced HIV (CD4 <200) may be severe and rapidly progressive. Antifungal therapy is essential; systemic treatment may be necessary. SD severity improves substantially with immune reconstitution on antiretroviral therapy.

Emerging Therapies

Newer Malassezia-targeted therapies and immune modulation strategies are under investigation. Oral terbinafine and newer triazoles are being studied for severe refractory cases. Probiotic modulation of skin microbiota is a promising area of research but lacks robust clinical trial evidence.

Frequently Asked Questions

Is seborrheic dermatitis the same as dandruff?

Seborrheic dermatitis and dandruff exist on a severity spectrum. Dandruff is mild seborrheic dermatitis — simple scaling without inflammation. True seborrheic dermatitis includes erythema, inflammation, and pruritus, typically visible on scalp, face, and upper trunk. The distinction is clinical: dandruff involves cosmetic scaling; seborrheic dermatitis is an inflammatory condition.

Is seborrheic dermatitis contagious?

No, seborrheic dermatitis is not contagious. It results from altered immune response to Malassezia yeast (normal skin flora), genetic predisposition, and skin barrier dysfunction. The condition depends on individual factors, not pathogenic transmission. You cannot acquire it from other people or give it to others through contact or shared items.

Why does seborrheic dermatitis keep coming back?

Seborrheic dermatitis is chronic-relapsing because the underlying immune sensitivity to Malassezia persists. Environmental triggers (stress, winter weather, poor sleep) prompt flares. Malassezia species multiply in sebum-rich areas, reinstating inflammation. Chronic suppressive therapy (regular antifungal shampoos 2-3x weekly) is necessary; cure is rare and typically only achieved through long-term management.

What shampoo ingredients actually work?

Evidence-supported active ingredients include zinc pyrithione (1-2%), ketoconazole (1-2%), selenium sulfide (1-2.5%), and salicylic acid (1-3%). Ketoconazole and zinc pyrithione are most consistently effective. Shampoos should contact scalp for 5-10 minutes before rinsing. Clinical trials show 70-85% improvement with regular use. Rotating agents every 4-6 weeks prevents resistance.

Does stress make seborrheic dermatitis worse?

Yes, psychological stress significantly exacerbates seborrheic dermatitis through neuroimmune pathways. Stress increases sebum production and alters immune tolerance to Malassezia. Studies show 60-75% of patients report stress-triggered flares. Stress management, sleep optimization, and moderate exercise reduce flare frequency and severity without replacing topical therapy.

What's the best treatment for facial seborrheic dermatitis?

Facial seborrheic dermatitis requires gentle management. Low-potency topical corticosteroids (hydrocortisone 1%) combined with antifungal agents (ketoconazole 2% cream) are first-line. Calcineurin inhibitors (tacrolimus) are effective steroid-sparing options. Non-medicated cleansers and fragrance-free moisturizers support barrier function. Avoid overuse of topical steroids (atrophy risk on facial skin).

References